AG˹ٷ

STOCK TITAN

[8-K] AEye, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

HeartSciences, Inc. (Nasdaq: HSCS/HSCSW) filed an 8-K to update investors on its ongoing Regulation A offering and a note-for-equity exchange.

  • The Form 1-A, qualified on 10 Mar 2025, permits sale of up to 4,285,714 Units at $3.50 each (maximum proceeds $15.0 million). Each Unit comprises one share of Series D Preferred Stock and one warrant exercisable at $5.00 for one common share.
  • Through 29 Jul 2025, the company has closed on $4.3 million in gross proceeds, issuing 1,241,188 Units.
  • Holders have converted 850,981 Series D shares into an equal number of common shares (the “Reg A Issuance�).
  • Separately, the company exchanged $1.105 million principal of a September 2024 unsecured promissory note for 301,111 common shares, reducing the note by that amount (the “Debt Exchange�).
  • Post-transactions, 2,244,247 common shares are issued and outstanding as of 29 Jul 2025.

No financial statements were included; the filing was limited to disclosure of these capital transactions.

HeartSciences, Inc. (Nasdaq: HSCS/HSCSW) ha presentato un modulo 8-K per aggiornare gli investitori sulla sua offerta continua ai sensi del Regulation A e su uno scambio di nota per azioni.

  • Il modulo 1-A, qualificato il 10 marzo 2025, consente la vendita di un massimo di 4.285.714 Unit a $3,50 ciascuna (proventi massimi $15,0 milioni). Ogni Unit comprende una azione di Serie D Preferred Stock e un warrant esercitabile a $5,00 per una azione ordinaria.
  • Fino al 29 luglio 2025, la società ha raccolto $4,3 milioni di proventi lordi, emettendo 1.241.188 Unit.
  • I detentori hanno convertito 850.981 azioni Serie D in un numero uguale di azioni ordinarie (la “Emissione Reg A�).
  • Separatamente, la società ha scambiato un importo principale di $1,105 milioni di una nota di debito non garantita con scadenza settembre 2024 per 301.111 azioni ordinarie, riducendo la nota di tale importo (lo “Scambio di Debito�).
  • Dopo queste operazioni, risultano emesse e in circolazione 2.244.247 azioni ordinarie al 29 luglio 2025.

Non sono stati inclusi bilanci; il deposito si è limitato alla divulgazione di queste operazioni di capitale.

HeartSciences, Inc. (Nasdaq: HSCS/HSCSW) presentó un formulario 8-K para actualizar a los inversores sobre su oferta continua bajo la Regulación A y un intercambio de nota por acciones.

  • El Formulario 1-A, calificado el 10 de marzo de 2025, permite la venta de hasta 4.285.714 Unidades a $3.50 cada una (ingresos máximos $15.0 millones). Cada Unidad incluye una acción de Serie D Preferred Stock y un warrant ejercitable a $5.00 por una acción común.
  • Hasta el 29 de julio de 2025, la compañía ha cerrado con $4.3 millones en ingresos brutos, emitiendo 1.241.188 Unidades.
  • Los tenedores han convertido 850.981 acciones Serie D en un número igual de acciones comunes (la “Emisión Reg A�).
  • Por separado, la compañía intercambió $1.105 millones de principal de una nota promisoria no garantizada con vencimiento en septiembre de 2024 por 301.111 acciones comunes, reduciendo la nota en esa cantidad (el “Intercambio de Deuda�).
  • Tras las transacciones, hay 2.244.247 acciones comunes emitidas y en circulación al 29 de julio de 2025.

No se incluyeron estados financieros; la presentación se limitó a la divulgación de estas transacciones de capital.

HeartSciences, Inc. (나스�: HSCS/HSCSW)� 진행 중인 Regulation A 공모 � 채권-주식 교환� 대� 투자자들에게 업데이트하기 위해 8-K 보고서를 제출했습니다.

  • 2025� 3� 10� 승인� Form 1-A� 단가 $3.50� 최대 4,285,714 단위� 판매� � 있도� 허용합니�(최대 수익 $15.0백만). � 단위� 시리� D 우선� 1주와 $5.00� 보통� 1주로 행사� � 있는 워런� 1개로 구성됩니�.
  • 2025� 7� 29일까지 회사� $4.3백만� � 수익� 확보하며 1,241,188 단위� 발행했습니다.
  • 보유자들읶 850,981 시리� D 주식� 동일 수량� 보통주로 전환했습니다(“Reg A 발행�).
  • 별도�, 회사� 2024� 9� 만기 무담� 약속어음 원금 $1.105백만301,111 보통주로 교환하여 해당 금액만큼 어음� 감소시켰습니�(“부� 교환�).
  • 거래 �, 2025� 7� 29� 기준으로 2,244,247 보통주가 발행 � 유통 중입니다.

재무제표� 포함되지 않았으며, 제출 내용은 이러� 자본 거래 공개� 한정되었습니�.

HeartSciences, Inc. (Nasdaq : HSCS/HSCSW) a déposé un formulaire 8-K pour informer les investisseurs de son offre en cours sous Regulation A et d’un échange de note contre actions.

  • Le formulaire 1-A, qualifié le 10 mars 2025, autorise la vente jusqu’� 4 285 714 unités à 3,50 $ chacune (produits maximum de 15,0 millions de dollars). Chaque unité comprend une action de série D Preferred Stock et un warrant exerçable à 5,00 $ pour une action ordinaire.
  • Jusqu’au 29 juillet 2025, la société a levé 4,3 millions de dollars de produits bruts, émettant 1 241 188 unités.
  • Les détenteurs ont converti 850 981 actions de série D en un nombre égal d’actions ordinaires (l’� émission Reg A »).
  • Séparément, la société a échangé 1,105 million de dollars de principal d’une note non garantie échéant en septembre 2024 contre 301 111 actions ordinaires, réduisant ainsi la note de ce montant (l’� échange de dette »).
  • Après ces opérations, 2 244 247 actions ordinaires sont émises et en circulation au 29 juillet 2025.

Aucun état financier n’a été inclus ; le dépôt s’est limité à la divulgation de ces opérations de capital.

HeartSciences, Inc. (Nasdaq: HSCS/HSCSW) hat eine 8-K-Meldung eingereicht, um Investoren über das laufende Regulation A-Angebot und einen Schulden-gegen-Aktien-Tausch zu informieren.

  • Das am 10. März 2025 qualifizierte Formular 1-A erlaubt den Verkauf von bis zu 4.285.714 Einheiten zu je 3,50 $ (maximaler Erlös 15,0 Mio. $). Jede Einheit besteht aus einer Aktie der Serie D Preferred Stock und einem Warrant, der zum Preis von 5,00 $ für eine Stammaktie ausgeübt werden kann.
  • Bis zum 29. Juli 2025 hat das Unternehmen Bruttoerlöse von 4,3 Mio. $ erzielt und 1.241.188 Einheiten ausgegeben.
  • Inhaber haben 850.981 Serie D-Aktien in eine gleiche Anzahl von Stammaktien umgewandelt (die „Reg A-Ausgabe�).
  • Separat hat das Unternehmen einen ungesicherten Schuldschein mit Fälligkeit September 2024 im Nennwert von 1,105 Mio. $ gegen 301.111 Stammaktien getauscht, wodurch die Schuld um diesen Betrag reduziert wurde (der „Schulden-Tausch�).
  • Nach den Transaktionen sind zum 29. Juli 2025 2.244.247 Stammaktien ausgegeben und im Umlauf.

Es wurden keine Finanzberichte beigefügt; die Meldung beschränkte sich auf die Offenlegung dieser Kapitaltransaktionen.

Positive
  • $4.3 million in new equity capital raised through Reg A offering
  • Conversion of preferred stock simplifies capital stack and removes dividend obligations
  • Debt exchange reduces principal by $1.105 million, lowering leverage
Negative
  • Issuance of 1.15 million new common shares produces immediate dilution
  • Reg A proceeds to date represent only about 29 % of the $15 million target, leaving financing needs unresolved

Insights

TL;DR: Raises $4.3 m cash, cuts $1.1 m debt; dilution increases share count to 2.24 m—net impact modestly positive.

The Reg A offering brings in only 29 % of the $15 m target but still strengthens liquidity without bank leverage. Converting preferred into common simplifies capital structure, while the note exchange eliminates unsecured debt and interest expense. However, issuing 1.15 m new common shares (850 k from conversion plus 301 k for debt) dilutes existing holders. Overall, cash in and debt out outweigh dilution for a micro-cap striving to fund operations.

TL;DR: Transactions follow standard Reg A mechanics; no governance red flags detected.

The company properly disclosed conversions and debt exchange under Item 8.01 and updated outstanding share count, maintaining transparency. No preferential terms beyond market-standard warrant pricing are noted. Reducing unsecured debt improves balance-sheet risk. The filing is routine and non-controversial.

HeartSciences, Inc. (Nasdaq: HSCS/HSCSW) ha presentato un modulo 8-K per aggiornare gli investitori sulla sua offerta continua ai sensi del Regulation A e su uno scambio di nota per azioni.

  • Il modulo 1-A, qualificato il 10 marzo 2025, consente la vendita di un massimo di 4.285.714 Unit a $3,50 ciascuna (proventi massimi $15,0 milioni). Ogni Unit comprende una azione di Serie D Preferred Stock e un warrant esercitabile a $5,00 per una azione ordinaria.
  • Fino al 29 luglio 2025, la società ha raccolto $4,3 milioni di proventi lordi, emettendo 1.241.188 Unit.
  • I detentori hanno convertito 850.981 azioni Serie D in un numero uguale di azioni ordinarie (la “Emissione Reg A�).
  • Separatamente, la società ha scambiato un importo principale di $1,105 milioni di una nota di debito non garantita con scadenza settembre 2024 per 301.111 azioni ordinarie, riducendo la nota di tale importo (lo “Scambio di Debito�).
  • Dopo queste operazioni, risultano emesse e in circolazione 2.244.247 azioni ordinarie al 29 luglio 2025.

Non sono stati inclusi bilanci; il deposito si è limitato alla divulgazione di queste operazioni di capitale.

HeartSciences, Inc. (Nasdaq: HSCS/HSCSW) presentó un formulario 8-K para actualizar a los inversores sobre su oferta continua bajo la Regulación A y un intercambio de nota por acciones.

  • El Formulario 1-A, calificado el 10 de marzo de 2025, permite la venta de hasta 4.285.714 Unidades a $3.50 cada una (ingresos máximos $15.0 millones). Cada Unidad incluye una acción de Serie D Preferred Stock y un warrant ejercitable a $5.00 por una acción común.
  • Hasta el 29 de julio de 2025, la compañía ha cerrado con $4.3 millones en ingresos brutos, emitiendo 1.241.188 Unidades.
  • Los tenedores han convertido 850.981 acciones Serie D en un número igual de acciones comunes (la “Emisión Reg A�).
  • Por separado, la compañía intercambió $1.105 millones de principal de una nota promisoria no garantizada con vencimiento en septiembre de 2024 por 301.111 acciones comunes, reduciendo la nota en esa cantidad (el “Intercambio de Deuda�).
  • Tras las transacciones, hay 2.244.247 acciones comunes emitidas y en circulación al 29 de julio de 2025.

No se incluyeron estados financieros; la presentación se limitó a la divulgación de estas transacciones de capital.

HeartSciences, Inc. (나스�: HSCS/HSCSW)� 진행 중인 Regulation A 공모 � 채권-주식 교환� 대� 투자자들에게 업데이트하기 위해 8-K 보고서를 제출했습니다.

  • 2025� 3� 10� 승인� Form 1-A� 단가 $3.50� 최대 4,285,714 단위� 판매� � 있도� 허용합니�(최대 수익 $15.0백만). � 단위� 시리� D 우선� 1주와 $5.00� 보통� 1주로 행사� � 있는 워런� 1개로 구성됩니�.
  • 2025� 7� 29일까지 회사� $4.3백만� � 수익� 확보하며 1,241,188 단위� 발행했습니다.
  • 보유자들읶 850,981 시리� D 주식� 동일 수량� 보통주로 전환했습니다(“Reg A 발행�).
  • 별도�, 회사� 2024� 9� 만기 무담� 약속어음 원금 $1.105백만301,111 보통주로 교환하여 해당 금액만큼 어음� 감소시켰습니�(“부� 교환�).
  • 거래 �, 2025� 7� 29� 기준으로 2,244,247 보통주가 발행 � 유통 중입니다.

재무제표� 포함되지 않았으며, 제출 내용은 이러� 자본 거래 공개� 한정되었습니�.

HeartSciences, Inc. (Nasdaq : HSCS/HSCSW) a déposé un formulaire 8-K pour informer les investisseurs de son offre en cours sous Regulation A et d’un échange de note contre actions.

  • Le formulaire 1-A, qualifié le 10 mars 2025, autorise la vente jusqu’� 4 285 714 unités à 3,50 $ chacune (produits maximum de 15,0 millions de dollars). Chaque unité comprend une action de série D Preferred Stock et un warrant exerçable à 5,00 $ pour une action ordinaire.
  • Jusqu’au 29 juillet 2025, la société a levé 4,3 millions de dollars de produits bruts, émettant 1 241 188 unités.
  • Les détenteurs ont converti 850 981 actions de série D en un nombre égal d’actions ordinaires (l’� émission Reg A »).
  • Séparément, la société a échangé 1,105 million de dollars de principal d’une note non garantie échéant en septembre 2024 contre 301 111 actions ordinaires, réduisant ainsi la note de ce montant (l’� échange de dette »).
  • Après ces opérations, 2 244 247 actions ordinaires sont émises et en circulation au 29 juillet 2025.

Aucun état financier n’a été inclus ; le dépôt s’est limité à la divulgation de ces opérations de capital.

HeartSciences, Inc. (Nasdaq: HSCS/HSCSW) hat eine 8-K-Meldung eingereicht, um Investoren über das laufende Regulation A-Angebot und einen Schulden-gegen-Aktien-Tausch zu informieren.

  • Das am 10. März 2025 qualifizierte Formular 1-A erlaubt den Verkauf von bis zu 4.285.714 Einheiten zu je 3,50 $ (maximaler Erlös 15,0 Mio. $). Jede Einheit besteht aus einer Aktie der Serie D Preferred Stock und einem Warrant, der zum Preis von 5,00 $ für eine Stammaktie ausgeübt werden kann.
  • Bis zum 29. Juli 2025 hat das Unternehmen Bruttoerlöse von 4,3 Mio. $ erzielt und 1.241.188 Einheiten ausgegeben.
  • Inhaber haben 850.981 Serie D-Aktien in eine gleiche Anzahl von Stammaktien umgewandelt (die „Reg A-Ausgabe�).
  • Separat hat das Unternehmen einen ungesicherten Schuldschein mit Fälligkeit September 2024 im Nennwert von 1,105 Mio. $ gegen 301.111 Stammaktien getauscht, wodurch die Schuld um diesen Betrag reduziert wurde (der „Schulden-Tausch�).
  • Nach den Transaktionen sind zum 29. Juli 2025 2.244.247 Stammaktien ausgegeben und im Umlauf.

Es wurden keine Finanzberichte beigefügt; die Meldung beschränkte sich auf die Offenlegung dieser Kapitaltransaktionen.

false 0001818644 0001818644 2025-07-30 2025-07-30 0001818644 LIDR:CommonStockParValue0.0001PerShareMember 2025-07-30 2025-07-30 0001818644 LIDR:WarrantsToReceiveOneShareOfCommonStockMember 2025-07-30 2025-07-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 30, 2025

 

AEYE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-39699   37-1827430
(State or other jurisdiction   (Commission File Number)   (IRS Employer Identification No.)
of incorporation)        

 

4670 Willow Road, Suite 125, Pleasanton, California   94588
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (925) 400-4366

 

 
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share LIDR The Nasdaq Stock Market LLC
Warrants to receive one share of Common Stock LIDRW The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 
 
Item 8.01.Other Events.

 

On July 30, 2025, AEye, Inc. (the “Company”) received written notice from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”) by maintaining a minimum closing bid price of the Company’s common stock of at least $1.00 per share for the ten consecutive business day period from July 16, 2025 to July 29, 2025 and that this matter is now closed.

As previously reported, on March 11, 2025, Nasdaq notified the Company that for the prior 30 consecutive business days, the closing bid price for the Company’s common stock had been below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market pursuant to Rule 5550(a)(2) and that the Company had 180 days, or until September 8, 2025, to evidence compliance with Rule 5550(a)(2).

 

On July 30, 2025, the Company issued a press release disclosing the fact that it has regained compliance with the minimum closing bid price requirement. A copy of the press release is included herewith as Exhibit 99.1 and incorporated herein by reference.

 

Item 9.01.Financial Statement and Exhibits.

 

(d)Exhibits.

 

Exhibit Number Description
   
99.1 Press Release dated July 30, 2025
   
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

 

 

 

 

 

 

 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    AEye, Inc.
     
Dated: July 30, 2025    
    By: /s/ Andrew S. Hughes
      Andrew S. Hughes
      Senior Vice President, General Counsel & Corporate Secretary

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FAQ

How much has HeartSciences (HSCS) raised in its 2025 Reg A offering?

As of 29 Jul 2025, HeartSciences has raised $4.3 million in gross proceeds.

What securities are included in each Unit sold by HSCS?

Each Unit contains one Series D Preferred share and one warrant to buy one common share at $5.00.

How many common shares are now outstanding after the conversions and debt exchange?

The company reports 2,244,247 common shares issued and outstanding as of 29 Jul 2025.

What amount of debt was eliminated through the note-for-equity exchange?

HeartSciences exchanged $1.105 million of an unsecured promissory note for 301,111 common shares.

What is the maximum amount HeartSciences can still raise under its Reg A offering?

Up to $10.7 million remains available, given the $15 million cap and $4.3 million raised to date.
Aeye Inc

NASDAQ:LIDR

LIDR Rankings

LIDR Latest News

LIDR Latest SEC Filings

LIDR Stock Data

68.83M
18.03M
8.06%
6.99%
8.08%
Software - Infrastructure
Motor Vehicle Parts & Accessories
United States
PLEASANTON